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Abstract
Background: Dementia outcomes include memory loss, language impairment, re-
duced quality of life and personality changes. Research suggests that outcomes se-
lected for dementia clinical trials might not be the most important to people affected.
Objective: One of the goals of the ‘Real world Outcomes across the Alzheimer's 
Disease spectrum for better care: Multi- modal data Access Platform’ (ROADMAP) 
project was to identify important outcomes from the perspective of people with de-
mentia and their caregivers. We review how ROADMAP's Public Involvement shaped 
the programme, impacted the research process and gave voice to people affected by 
dementia.
Design: The European Working Group of People with Dementia (EWGPWD) were 
invited to participate. In- person consultations were held with people with demen-
tia and caregivers, with advance information provided on ROADMAP activities. 
Constructive criticism of survey content, layout and accessibility was sought, as were 
views and perspectives on terminology and key concepts around disease progression.
Results: The working group provided significant improvements to survey accessibil-
ity and acceptability. They promoted better understanding of concepts around dis-
ease progression and how researchers might approach measuring and interpreting 
findings. They effectively expressed difficult concepts through real- world examples.
Conclusions: The role of the EWGPWD in ROADMAP was crucial, and its impact was 
highly influential. Involvement from the design stage helped shape the ethos of the 
programme and ultimately its meaningfulness.
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1  | INTRODUC TION
Alzheimer's disease is the most common cause of dementia, ac-
counting for 50%- 70% of cases.1,2 It is associated with a range of 
outcomes, including memory loss, language impairment, increased 
dependency, reduced quality of life and personality changes.3,4 
Research has suggested that outcomes selected for clinical trials in 
dementia might not be important to people with the condition and 
their caregivers.3- 6 Selecting outcomes of importance to key stake-
holders reportedly improves the relevance and quality of research 
results, makes studies more acceptable to potential participants and 
increases participant recruitment and retention.7- 9
One of the goals of the ‘Real world Outcomes across the 
Alzheimer's Disease spectrum for better care: Multi- modal data 
Access Platform’ (ROADMAP) project10 was to identify the out-
comes of Alzheimer's disease that are most important to people 
with the disease and their caregivers, understand what would con-
stitute a meaningful delay in disease progression from their per-
spectives and create a disease progression matrix that highlights 
the outcomes of greatest importance at the various stages of the 
disease (i.e. from pre- clinical Alzheimer's disease to Alzheimer's 
dementia). Findings would inform the development of a data 
platform that integrates multiple sources of real- world data re-
lated to Alzheimer's disease, called the Data Cube,11 to enhance 
researchers' understanding of disease progression in the real 
world. To achieve this goal, ROADMAP involved people with de-
mentia and caregivers in the research process, not only as par-
ticipants but also as advisors. This is in keeping with the concept 
of ‘Public Involvement’ (PI) (formerly known as Public and Patient 
Involvement [PPI]).12
PI is not a specific method, but an approach to involving people 
in research other than as research participants. It is about conduct-
ing research with and by people with a particular condition and/or 
members of the public, rather than research being done to, for or 
about them.13- 16 PI can be seen as a ‘means to an end’, in the sense of 
attempting to improve the quality, relevance and utility of research 
(from both research and user perspective), but also as ‘an end in it-
self’, in the sense of being linked to democracy (e.g. democratic deci-
sion making, public accountability, legitimization and transparency), 
people having rights (e.g. a right to voice, a right to be involved in re-
search relevant to one's own condition) and ethical principles of jus-
tice and fairness.12 Involvement can occur at all stages of research, 
including prioritization of studies,17,18 design and management of 
research,19 identification of health outcomes,20,21 data collection 
and analysis22,23 and dissemination of findings.24
Over the last few decades, there has been an increased inter-
est in involving people living with dementia in PI in dementia re-
search.25 Several national and European- funded research projects 
have developed different approaches and methodologies to achieve 
this,25- 27 although information regarding the impact of PI activities 
for researchers, the people involved and society is still lacking. From 
the perspective of people affected by the condition, PI in dementia 
research is considered as fundamental and should become the norm, 
but efforts still need to be made to ensure PI is inclusive of a diverse 
set of people.28
1.1 | Aims
This article reviews how ROADMAP's PI consultations
1. shaped the design and content of the stakeholder surveys,
2. had an impact on other issues related to the research process in 
general and
3. gave voice to people with dementia and caregivers.
We believe it is a success story for meaningful and active in-
volvement of people with dementia and their caregivers in the re-
search process.
2  | ORGANIZ ATION OF PUBLIC 
INVOLVEMENT IN ROADMAP
2.1 | Selection of the people involved
2.1.1 | People with dementia
People with dementia from the European Working Group of 
People with dementia (EWGPWD) took part in this consultation. 
The EWGPWD is composed of people from different countries 
and was set up by Alzheimer Europe in 2012.29 The members 
of the group had all been nominated by their national Alzheimer 
Associations. They work in collaboration with Alzheimer Europe, 
contributing towards Alzheimer Europe's work and research pro-
jects in which it is involved. The group works to ensure that the 
Public contribution: People with dementia and their carers were involved through 
structured consultations and invited to provide feedback on project materials, meth-
ods and insight into terminology and relevant concepts.
K E Y W O R D S
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activities, projects and meetings of Alzheimer Europe duly reflect 
the priorities and views of people with dementia. All members 
of the EWGPWD are in the mild or moderate stages of demen-
tia and have capacity to understand what is being asked of them. 
Alzheimer Europe was a member of the ROADMAP consortium, 
and the EWGPWD agreed to be involved in this consultation ac-
tivity as part of their PI remit. Overall, nine people with dementia 
(eight female and one male) from the Czech Republic, Germany, 
Portugal, the Republic of Ireland, Sweden and the United Kingdom 
were involved in the consultations.
2.1.2 | Informal caregivers
Members of the EWGPWD are typically accompanied to meetings 
by a relative, friend and occasionally by a member of staff from an 
Alzheimer Association. However, on this occasion, the accompany-
ing individuals were invited to be involved in a separate consulta-
tion for caregivers. Overall, seven caregivers (five female and two 
male) from Portugal, the Republic of Ireland, Sweden and the United 
Kingdom were involved in the consultations.
2.2 | Planning and conducting the public 
involvement consultations
Consultations with the EWGPWD and their caregivers were held 
in Luxembourg on the 4th and 5th of September 2017 and were 
conducted in accordance with Alzheimer Europe's position on PI,16 
which was developed in collaboration with the EWGPWD and the 
INTERDEM research groups.30 Alzheimer Europe has great experi-
ence in preparing and conducting PI work with people with dementia. 
The schedule was developed by Alzheimer Europe in collaboration 
with ROADMAP members from the University of Edinburgh. In ad-
dition, the Dementia Engagement and Empowerment Project (DEEP) 
guidelines31 were taken into account when developing the materials 
and the schedule.
Involvement consisted of two concurrent consultations (one 
for the members of the EWGPWD and the other for their caregiv-
ers) that ran over the course of 2 days. Consultations were con-
ducted in English, which is standard practice for the EWGPWD. 
All people involved received information about the project and 
the topics to be discussed 2 weeks prior to the consultation. In 
addition, on the first day of the consultation, a presentation about 
ROADMAP, relevant concepts in the project (e.g. real- word evi-
dence and outcomes in research) and why PI was important in the 
project, was provided.
The consultations were organized in such a way as to ensure that 
the EWGPWD and their caregivers were actively involved in the 
design and interpretation of ROADMAP's research activities. They 
facilitated productive interaction between the research team and 
stakeholders and informed and guided the translation of the results. 
The key discussion topics aimed
1. to provide constructive criticism of the stakeholder surveys, 
relating to its content, layout and accessibility and
2. to share views and perspectives on
a. their personal experiences of disease progression and the out-
comes that typically indicate the disease is progressing,
b. staging disease progression and
c. what would constitute a meaningful delay in disease 
progression.
The consultations were jointly planned and carried out by mem-
bers of ROADMAP from the University of Edinburgh and staff of 
Alzheimer Europe with expertise in PI in dementia. Alzheimer 
Europe's position paper on PI in dementia research highlights the 
different issues that need to be carefully considered in PI, includ-
ing planning the involvement, establishing roles and responsibilities, 
providing the necessary support, managing information and input 
from PI, recognizing the contribution of people with dementia in-
volved in research in this way, promoting and protecting the rights 
and well- being of people with dementia and promoting an inclu-
sive approach and the necessary infrastructure for PI in dementia 
research.16 Reflecting on and addressing these issues was key for 
the quality of the PI activities. These principles were addressed in 
the consultations and a number of factors were identified which im-
proved their quality:
1. Having a clear introduction to the topic of interest, written 
without jargon and giving a detailed lay explanation of the 
issue.
2. Providing this information in writing in advance: at least 2 weeks 
in advance of the activity.
3. Being precise about what is wanted from the group and from their 
involvement in the project.
4. Explaining the topic of interest again on the day and giving time 
to answer any questions or explain the issue in further detail as 
required.
5. Limiting the activities to a set time and taking adequate breaks 
between each consultation activity.
6. Ensuring people talk one at a time and avoiding individuals talking 
over each other.
7. Allowing time (gaps in the conversations) for the members to re-
flect on and add to the discussion when they are ready.
2.3 | Synthesis of discussions
With the authorization of all members of the EWGPWD and their 
caregivers, all consultation activities were audio- recorded and notes 
were made. This enabled the moderators of the consultations to 
be fully involved in the discussions and to be attentive to possible 
needs of members of the EWGPWD (e.g. signs of fatigue, irritation 
or difficulties understanding). After the consultation, recordings 
were transcribed verbatim. The notes taken during the meeting and 
photographs of the different activities (e.g. flipchart summaries and 
prioritization activity) were also used for the analysis.
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A thematic analysis approach was taken to organize the input 
provided during the consultations in a systematic and meaning-
ful way. This involved the researchers from Edinburgh University 
reading the transcripts repeatedly and grouping the different per-
spectives and ideas into possible topics, for example what out-
comes are important and why are specific outcomes important. 
This was reviewed and discussed with the other facilitators in-
volved (Alzheimer Europe) and later with the people involved in 
the PI activity.
The report was presented to the EWGPWD on 27 June 2018 
in Brussels to confirm that their input had been represented accu-
rately. Following this, findings were reported to ROADMAP's Expert 
Advisory Group32 on 29 June 2018 in Amsterdam, to discuss the 
relevance of the group's input and address any gaps. The subsequent 
findings and the conclusions drawn were agreed by all parties.
3  | IMPAC T OF PUBLIC INVOLVEMENT ON 
THE ROADMAP STUDY
3.1 | Survey refinement
The survey had been drafted with the intention that it would be com-
pleted online and in paper by people with dementia, their caregivers 
and health- care professionals throughout Europe. It included a list 
of outcomes related to Alzheimer's disease, with the intention of 
asking participants to rate how important each outcome was with 
regard to assessing a meaningful delay in disease progression, in ad-
dition to questions relating to disease stage, caregiving duties and 
demographics.33
The EWGPWD provided constructive criticism of the survey de-
sign and content. An important issue addressed by the members of 
the EWGPWD and caregivers was related to the terminology used 
to refer to Alzheimer's disease in the survey. Important conceptual 
changes were made in this regard based on the feedback provided 
in the consultation. The original survey used the terms Alzheimer's 
disease and dementia. Members of the EWGPWD felt this was con-
fusing and that many people with dementia and caregivers would 
not be familiar with the difference between both terms (i.e. new 
conceptualization of Alzheimer disease including pre- dementia as 
well as dementia stages). It was therefore suggested to use the term 
dementia and, if necessary, to separately refer to the pre- dementia 
stages. It was also advocated to include people with any type of de-
mentia in the study and not just Alzheimer's as often; in ‘real life’, 
people are not aware of their differential diagnosis, or their diagnosis 
is mixed (e.g. Alzheimer's and another type of dementia). Another 
important concern was in relation to the accessibility of the survey. 
Their suggestions have been compiled into a list of ‘dos’ and ‘don'ts’ 
Category Do Don't
Format and style Include questions with check boxes or yes/no 
answers, as they are easier to comprehend
Use a small or ineligible 
font size
Use bullet points, colour and imagery where 
possible
Use bold or italicised 
text
Language: clarity Consider how questions are asked e.g. ask for 
date of birth rather than age, as this is easier 
to remember
Use words with 
multiple meanings or 
homonyms
Language: tone Make questions short, simple and direct Make questions 
passive, repetitive or 
patronising
Support and ease 
of access
Carefully consider survey distribution 
methods, e.g. do not leave surveys in a 
memory clinic reception as these will likely 
be ignored
If administered by a professional, make sure 
they are adequately trained and understand 
living with dementia
Use multiple survey mediums e.g. paper and 
electronic
Effort and focus 
required
Provide a clear indication of how long the 
survey will take to complete
Include questions that 
require a large amount 
of writing or typing, 
e.g. ‘please expand or 
add more information 
about your choice’
Make the survey short
Keep in mind participants' fatigue or stress 
when developing questions
TA B L E  1   Survey refinements 
suggested by the EWGPWD
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with regard to developing surveys for people with dementia, shown 
in Table 1.
Input from PI was used to clarify and simplify some terms and 
questions in the survey which was ultimately perceived as more 
accessible and clear by the people with dementia and caregivers 
involved in the PI activity. Following the feedback provided in the 
PI consultation, the survey was completed by 456 people, includ-
ing 74 people with dementia, 144 caregivers and 238 health- care 
professionals.33
3.2 | Enhancing our understanding of key concepts
The consultations provided relevant input for the ROADMAP project 
regarding the topics of important outcomes, disease progression, 
staging of dementia and meaningful delay in dementia progression.
3.2.1 | Meaningful outcomes
An important goal of the ROADMAP project was to identify out-
comes that are important to people with dementia and their caregiv-
ers. In the context of the PI consultation, the EWGPWD and their 
caregivers raised a number of outcomes that they considered im-
portant for assessing disease progression, or that would constitute 
a meaningful delay in disease progression if preserved. A total of 
38 outcomes were identified, and these were organized into eight 
overarching domains, namely cognitive abilities, functional abili-
ties, behavioural and neuropsychiatric symptoms, quality of life of 
the person with dementia, impact on carers, medical investigations, 
mortality and comorbidities, and significant disease- related life 
events. These outcomes have been integrated into key ROADMAP 
outputs.11,33
3.2.2 | Disease progression
Progression can be a sensitive and difficult topic. Nevertheless, as 
for any other medical condition, understanding the progression of 
dementia is very important for people affected by the condition. 
Progression was described as a complex issue, and in particular, peo-
ple with dementia highlighted the need to consider how the experi-
ence of multiple symptoms can influence disease progression. For 
example, individual symptoms, when combined, may influence the 
perception of disease progression. They also explained that people 
with dementia could sometimes be misunderstood because of be-
havioural or communication problems and may experience unusual 
emotional responses in ‘normal’ circumstances. They explained that 
together, these could lead to relationship problems and isolation, 
which impacted their quality of life and their perception of the se-
verity of their dementia.
It was recommended that the researchers should consider the 
following series of issues when thinking about disease progression.
Assessing and measuring progression
Overall, the groups were of the opinion that brain scans can be use-
ful for confirming disease progression and diagnosis, but they cur-
rently hold little meaning in terms of experience of symptoms in 
everyday life, hence lacking tangible benefit. Overall, this lack of 
connection between the experience of symptoms and the results 
of scans was considered to limit their usefulness when identifying 
disease progression.
In relation to measurement scales and tests (e.g. pen and paper 
tests), they highlighted that completing these tests can be disheart-
ening for some people (like ‘…watching yourself decline’). This, it was 
suggested, can lead to a loss of confidence, whilst offering little clar-
ity with regard to disease progression. They also raised the issue that 
such scales and tests often focus solely on cognitive measurements, 
with other important outcomes being overlooked, that is assessing 
cognition in the absence of everyday functioning.
I have a test every six months… And I've actually just 
told them that I'm not doing it anymore, because every 
test I've done every six months it's never even, I'm not 
asking for miracles, but it's never even been the same. 
I always lose a point or a couple of points, so I've said 
right, I don't want to lose any more confidence, so I'm 
not bothered now. I know it's progressing, yeah. 
(EWGPWD member)
Personalization and building the individual's story
People with dementia and caregivers suggested that assessing pro-
gression should be personalized, as everyone's story is different and 
there is huge variability in symptom experience. Caregivers sug-
gested that living with the person with dementia is important for 
assessing and understanding progression, as new and recurrent be-
haviours can be observed. This allows for differentiation between 
true progression and simply having a ‘bad day’.
Taking a holistic perspective of people with dementia
It was highlighted that when looking at the progression of dementia, 
other comorbidities and impairments should be taken into account 
and, in particular, the potential impact of these on the progression 
or the perceived progression of the disease. This is important as 
they can directly influence assessment, for example poorer cogni-
tive or functional performance due to a comorbidity, as opposed to 
dementia.
3.2.3 | Staging dementia
It was generally perceived that existing scales to stage dementia do 
not always capture the individual's lived experience. However, there 
was a general consensus that the terms ‘mild – moderate – severe’ 
adequately captured the stages of the condition in a way that could 
be easily understood by people with dementia, as they provide a 
good approximation of how far a person's dementia has progressed.
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A number of issues were raised in relation to staging disease pro-
gression, which should be considered by researchers, discussed in 
turn.
Inconsistency and susceptibility to external influences
Some people felt that judgement of a person's stage can differ be-
tween clinicians, leading to inconsistencies. Further, assessing stage 
using clinical measures only provides a snapshot of the condition, 
which can be heavily influenced by factors like mood and the envi-
ronment in which the assessment took place. It was concluded that 
the assessment of stages should therefore be tailored to the indi-
vidual, given differences in the type of symptoms experienced and 
rate of progression.
Implications for daily life
The groups pointed out that staging dementia has implications for 
everyday life, such as the loss of a driving licence, self- determination, 
freedom of movement and management of finances. In some coun-
tries, restrictions can occur simply due to a diagnosis of dementia, 
without assessment of capacity or skills. Inversely, a few people re-
ported that diagnosis and the staging of dementia can lead to gaining 
rights or access to services in some countries that would otherwise 
be unavailable.
My belief is we require labelling for social work pro-
fessionals, in some people in day- to- day life, having 
labels is irrelevant, it's irrelevant for my dad. What 
is relevant is I needed an explanation for why [he] 
couldn't function and work in his 50s. 
(Caregiver)
Preferences for new staging frameworks
The EWGPWD and caregivers stated that new staging frameworks 
should account for fluctuations or variability in a person's condition, 
as current frameworks can be rigid and linear. This could be achieved 
by providing more flexibility between the boundaries of the stages.
The EWGPWD's feedback on the conceptualization of stages 
was fed into the survey design33 and ROADMAP's Data Cube11 as it 
was considered useful and meaningful to people with dementia and 
their caregivers.
3.2.4 | Meaningful delay
Three relevant, interconnected issues were addressed in this con-
text, namely delay before the onset of dementia, delaying the pro-
gression of dementia and the balance between longevity and quality 
of life.
Delaying the onset of dementia
It was felt that meaningful delay is a complex concept, which might 
not be clearly understood by some people. It would be important to 
clearly distinguish between cure, prevention and meaningful delay. 
Meaningful delay was described in positive terms and often linked 
to the idea of ‘enjoying or having some extra time’. Important issues 
when talking about a meaningful delay of the onset of dementia 
were related to the certainty that the person would eventually de-
velop dementia, how long such delay would be, the balance between 
potential risks and benefits (e.g. side- effects, having a faster dete-
rioration after the delay, better quality of life/independence) and 
the particular circumstances of each person (e.g. comorbidities, age, 
frailty). It was highlighted that the meaning of the delay may also 
depend on whether the person is or is not familiar with dementia.
Okay. It's to delay the onset. Onset to me means the 
start of dementia. Well I don't want to start having 
dementia, so give me the drug. But how do you know 
I'm going to get dementia? So to delay the onset, yeah 
give me the drug. [Laughs] But do I need it? 
(Caregiver)
Two members of the EWGPWD elaborated further.
A: If you haven't got dementia and know nothing about it then a 
drug that just delays it wouldn't have a big meaning, ‘if I'm 
going to get it why not just have it’…but if you know a lot 
about dementia then it would mean a big difference.
B: Yeah, because you know how it is, actually living with dementia…
A: You know how important it is… Yeah, how important an extra 
year or an extra month…
(EWGPWD members)
Delaying disease progression
The delay of disease progression was perceived as potentially having 
a bigger, more meaningful impact at the earliest stage of the condi-
tion. It was highlighted that delaying progression should be accom-
panied by experiencing a reduction of symptoms and improvement 
in the quality of life of the person. Delaying the progression in the 
advanced stages of the disease may be less helpful and arguably 
cruel. Again, balancing risk and benefit with regard to side- effects 
was seen as hugely important.
Longevity vs quality of life
The importance of quality of life was raised, with a consensus that 
there is little benefit in delaying progression and prolonging life 
if there is no benefit in terms of quality of life (i.e. maintaining or 
improving quality of life). Longevity was not deemed an important 
measure in its own right. Being able to guarantee a person with de-
mentia additional ‘good years’ was considered the greatest value.
I don't want it to happen but if it's going to happen, 
let's get on with it. That's why, if it can't be guaran-
teed, a good ten years…. 
(Caregiver)
     |  7DIAZ et Al.
Whilst some common themes were detected in relation to the con-
cept of meaningful delay, the groups agreed that an individual's own 
set of values was of priority when determining choices related to their 
life and treatment and believed that respect for such individual differ-
ences was paramount.
3.3 | Democracy, rights and justice
The EWGPWD and caregivers were keen to have their voices heard 
in the ROADMAP study (in the sense of having a ‘right to voice’), as 
well as sharing their experiences and perspectives based on living 
with dementia with the ROADMAP researchers. This was seen as 
involving mutual respect and being based on the principle of reci-
procity. Table 2 provides a summary of feedback provided by mem-
bers of the EWGPWD when asked to reflect on the PI process and 
to identify the most important messages they wished to pass on to 
ROADMAP researchers.34
3.4 | Key outputs and deliverables
The input of the EWGPWD and their caregivers has been incor-
porated into a number of key ROADMAP outputs, including a 
deliverable reporting stakeholder- generated lists of real- world 
evidence– related outcomes of Alzheimer's disease across the 
spectrum,33 a disease progression and outcome classification 
matrix33 that fed into the development of ROADMAP's Data 
Cube,11,35 a presentation at the Alzheimer's Disease International 
Conference 2018 ‘Women and Dementia’ session,36 presentations 
at the Alzheimer Europe 2018 Conference ‘Real- World Evidence in 
Alzheimer's Disease’ session,37 refinement of ROADMAP's stake-
holder survey, which was subsequently completed by 456 individ-
uals,33 and the present article.
Additionally, ROADMAP's Data Cube is being promoted and 
developed further in collaboration with the Neuronet project,38 
a collaborative effort aimed at bringing together the findings and 
learnings of 15 Innovative Medicines Initiative funded projects relat-
ing to neurodegeneration. The input of the EWGPWD in ROADMAP 
has had a lasting impact in the field of Alzheimer's disease and 
dementia.
4  | CONCLUSION
This paper presents an example of people affected by dementia in-
volved in PI activities in a particular European project and what im-
pact this involvement had on the ROADMAP project. The Alzheimer 
Europe's position paper16 highlights the importance of involving 
people affected by dementia from the very beginning and for their 
involvement to be continued until the end of the research project. In 
this project, people affected by dementia were involved in a 2- day 
consultation and at the end of the project. In addition, one person 
with dementia participated in the project's Expert Advisory Group.32 
The involvement of people affected by dementia could have been 
even more impactful had they been involved earlier on and through-
out the project.
Nevertheless, the views and reflections of people directly af-
fected by the condition had a strong impact on survey design and 
on the development and use of concepts throughout the whole 
project. People affected by dementia appreciated and enjoyed 
TA B L E  2   Reflections on ROADMAP's PI consultations from the 
EWGPWD and their caregivers
Impact level
Reflections from the EWGPWD and 
their caregivers
Researchers It was important to educate 
researchers about what it is like 
to live with dementia, to look at 
people with dementia as human 
beings and understand what their 
condition is like. The EWGPWD 
and their caregivers found sharing 
their experiences enriching
There is no need to rewind the 
clock. Researchers should try to 
collaborate more
People with dementia and 
carers
Providing feedback was important 
to the EWGPWD and their 
caregivers, as researchers often do 
not do this
Everyone with dementia has a 
contribution to make, regardless 
of their education level or 
background
Involving people with dementia in 
PI can change perceptions of what 
it is like to be involved in dementia 
research. The EWGPWD could 
return to their home countries and 
talk about their experiences of 
being involved in ROADMAP's PI 
consultations
Being involved in the ROADMAP 
consultations gave the EWGPWD 
confidence and hope and helped 
them better understand their own 
conditions
Research People with dementia and 
caregivers should be involved 
as early as possible and should 
continue to be involved throughout 
the research process
The researchers maintained a 
professional attitude, but never 
lost the human touch. This was 
viewed as very important to the 
consultations' success
Take feedback and advice from PI 
forward and incorporate it into the 
research, do not leave it to gather 
dust
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being involved in this way in the project. In addition, the discus-
sions helped the researchers to understand better the perspec-
tives of people affected by dementia with regard to issues that 
were important for the project, such as meaningful outcomes, pro-
gression and delay of the disease, and also to identify issues and 
concerns that should be taken into account when carrying out re-
search. The progression and potential delay of dementia are very 
important and sensitive topics for people affected by dementia. 
Assessing the progression of the disease is important and neces-
sary, but the potential impact that this may have on a person's 
well- being and quality of life also needs to be taken into account 
and addressed. The potential delay of the disease can give people 
hope, but it is also important that people understand clearly what 
it entails and its potential limitations. The individual experience 
and considering the person as a whole (including comorbidities, 
social and personal factors) were key messages for ROADMAP re-
searchers working on these topics.
Involvement of people with dementia and caregivers in research 
through PI is paramount, but requires careful consideration of how 
to plan and conduct it. This includes, amongst other issues, ensuring 
that relevant expertise, time and budget are available.
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